Every 8-K that First Tracks Biotherapeutics, Inc. (TRAX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TRAX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRAX filings page.
First Tracks Biotherapeutics, Inc. (TRAX) closed a private placement of an aggregate 6,106,870 shares of common stock on October 19, 2026. At closing, it entered a registration rights agreement requiring it to file or confidentially submit a resale registration statement covering the investors’ shares as promptly as reasonably practicable, and no later than 30 days following the closing date.
First Tracks Biotherapeutics, Inc. agreed to issue and sell 6,106,870 common shares to a limited group of institutional investors in a private placement at $32.75 per share. The company expects approximately $200 million in gross proceeds before placement agent fees and other offering expenses. The securities will be unregistered and issued in reliance on an exemption from Securities Act registration requirements.
The placement is expected to close on October 19, 2026, subject to customary closing conditions. First Tracks Biotherapeutics intends to use the proceeds for general corporate purposes, including clinical development of ANB033, a CD122 antagonist. At closing, the company will enter into a registration rights agreement requiring it to file or confidentially submit a resale registration statement as promptly as reasonably practicable and no later than 30 days following closing. The company had 35,909,814 common shares issued and outstanding as of October 12, 2026. Leerink Partners, Piper Sandler, UBS Investment Bank and Wells Fargo Securities are acting as placement agents.
First Tracks Biotherapeutics, Inc. (TRAX) reported positive top-line results from Cohort 1 of its Phase 1b ANB033 celiac disease trial. The 32 patients who completed dosing and a 14-day gluten challenge included 17 receiving ANB033 and 15 placebo. At Week 6, the least-squares mean change in villus-height-to-crypt-depth ratio was -0.17 with ANB033 and -0.66 with placebo, a +0.49 placebo-adjusted delta (p=0.009). Intraepithelial lymphocyte density changed -1.20 versus +18.83, a -20.03 placebo-adjusted delta (p<0.001).
During the challenge, symptoms did not increase in the ANB033 group; total symptom score differences were statistically significant from days 1–7, and moderate-to-severe symptom differences through days 1–12. The safety analysis covered 34 participants: no serious adverse events occurred; any adverse event was reported in 16 of 18 ANB033 participants (88.9%) and 16 of 16 placebo participants (100%). First Tracks anticipates Cohort 2 celiac top-line data in Q1 2027 and ANB033 eosinophilic esophagitis data in Q3 2027; it anticipates starting a late-stage celiac trial in 2027.
First Tracks Biotherapeutics, Inc. reported second quarter 2026 results and updated progress across its pipeline. The company highlighted its CD122 antagonist ANB033, with a Phase 1b trial in celiac disease fully enrolled in Cohort 1 and ongoing enrollment in Cohort 2, and noted that the U.S. FDA granted Fast Track designation for ANB033 in celiac disease. Top-line data are reaffirmed for Q4 2026 for Cohort 1, Q1 2027 for Cohort 2, and Q3 2027 for a Phase 1b trial in eosinophilic esophagitis, with plans to start Phase 2 trials in two additional indications in H1 2027.
Cash, cash equivalents and investments totaled $168.0 million as of June 30, 2026, and the company reiterates a projected cash runway into Q2 2028, including expansion of ANB033 into two new indications. Research and development expenses were $25.6 million for the quarter, down from $39.3 million a year earlier, while general and administrative expenses rose to $9.3 million from $6.6 million, largely due to separation-related legal costs. Net loss for the quarter was $33.4 million, or $0.95 per share, compared with a net loss of $42.4 million, or $1.47 per share, in the prior-year period.
First Tracks Biotherapeutics, Inc. entered into a new sublease on June 15, 2026 with AnaptysBio, Inc. for approximately 45,057 rentable square feet at 10770 Wateridge Circle in San Diego, California.
The initial sublease term runs for 12 months, with an option to extend for up to an additional period ending no later than April 4, 2028, if the company gives at least three months’ prior written notice. The company may also terminate the sublease at any time during the term with three months’ prior written notice.
Monthly payments under the sublease equal the Basic Rent and Additional Rent AnaptysBio owes under the existing master lease, and the company is responsible for charges for services it requests. The sublease is subordinate to the master lease and will end if AnaptysBio’s lease or right to possess the premises terminates.
First Tracks Biotherapeutics reported combined first quarter 2026 results and outlined progress across its immunology pipeline following separation from AnaptysBio. The company launched with $180 million in cash and cash equivalents on April 20, 2026 and expects a roughly two‑year cash runway to advance lead programs.
For the three months ended March 31, 2026, research and development expenses were $34.0 million, down from $41.5 million a year earlier, while general and administrative expenses rose to $18.9 million from $9.8 million, mainly due to separation and stock‑based compensation costs. Net loss was $50.5 million compared with $47.2 million in the prior‑year period.
At March 31, 2026, First Tracks reported cash and cash equivalents of $248.5 million, short‑term investments of $38.0 million and total assets of $290.6 million. The update highlighted ongoing Phase 1b trials of ANB033 in celiac disease and eosinophilic esophagitis, an End‑of‑Phase 2 FDA meeting for rosnilimab in rheumatoid arthritis, and a near‑complete Phase 1a trial of ANB101 in healthy volunteers.